Effect of pharmacological manipulations of neuropeptide Y and corticotropin-releasing factor neurotransmission on incubation of conditioned fear

Neuroscience

Volumn 164, Issue 4, 2009, Pages 1398-1406

  Pickens, C L ^a   Adams Deutsch, T ^a   Nair, S G ^a   Navarre, B M ^a   Heilig, M ^b   Shaham, Y ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

D Phe CRF(12 41); fear conditioning; incubation; MTIP; neuropeptide Y; PTSD

Indexed keywords

ASTRESSIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; CONDITIONING; CONTROLLED STUDY; FEAR; INCUBATION TIME; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN INTERACTION; RAT;

ACOUSTIC STIMULATION; ANIMALS; ARGININE; BENZAZEPINES; CONDITIONING, OPERANT; CORTICOTROPIN-RELEASING HORMONE; FEAR; MALE; NEUROPEPTIDE Y; PYRIDAZINES; RATS; RATS, LONG-EVANS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, NEUROPEPTIDE Y; SYNAPTIC TRANSMISSION; THIAZOLES; TIME FACTORS;

EID: 70449704038     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.09.079     Document Type: Article

References (65)

1. Andrews B., Brewin C.R., Philpott R., and Stewart L. Delayed-onset posttraumatic stress disorder: a systematic review of the evidence. Am J Psychiatry 164 9 (2007) 1319-1326
2. Annau Z., and Kamin L.J. The conditioned emotional response as a function of intensity of the US. J Comp Physiol Psychol 54 (1961) 428-432
3. Armony J.L., Servan-Schreiber D., Romanski L.M., Cohen J.D., and LeDoux J.E. Stimulus generalization of fear responses: effects of auditory cortex lesions in a computational model and in rats. Cereb Cortex 7 2 (1997) 157-165
4. Bacchi F., Mathe A.A., Jimenez P., Stasi L., Arban R., Gerrard P., and Caberlotto L. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 27 12 (2006) 3202-3207
5. Balogh S.A., Radcliffe R.A., Logue S.F., and Wehner J.M. Contextual and cued fear conditioning in C57BL/6J and DBA/2J mice: context discrimination and the effects of retention interval. Behav Neurosci 116 6 (2002) 947-957
6. Basso A.M., Spina M., Rivier J., Vale W., and Koob G.F. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl) 145 1 (1999) 21-30
7. Bouton M.E., and Bolles R.C. Role of conditioned contextual stimuli in reinstatement of extinguished fear. J Exp Psychol Anim Behav Process 5 4 (1979) 368-378
8. Britton K.T., Lee G., Vale W., Rivier J., and Koob G.F. Corticotropin releasing factor (CRF) receptor antagonist blocks activating and "anxiogenic" actions of CRF in the rat. Brain Res 369 1-2 (1986) 303-306
9. Broqua P., Wettstein J.G., Rocher M.N., Gauthier-Martin B., and Junien J.L. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6 3 (1995) 215-222
10. Clark J.T., Kalra P.S., Crowley W.R., and Kalra S.P. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115 1 (1984) 427-429
11. de Jongh R., Groenink L., van der Gugten J., and Olivier B. Light-enhanced and fear-potentiated startle: temporal characteristics and effects of alpha-helical corticotropin-releasing hormone. Biol Psychiatry 54 10 (2003) 1041-1048
12. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., Licinio J., Wong M.L., Chrousos G.P., Webster E., and Gold P.W. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140 1 (1999) 79-86
13. Diven K. Certain determinants in the conditioning of anxiety reactions. J Psychol Interdiscip Appl 3 (1937) 291-308
14. Doods H., Gaida W., Wieland H.A., Dollinger H., Schnorrenberg G., Esser F., Engel W., Eberlein W., and Rudolf K. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 384 2-3 (1999) R3-R5
15. Erb S., Shaham Y., and Stewart J. The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 18 14 (1998) 5529-5536
16. Estes W.K., and Skinner B.F. Some quantitative properties of anxiety. J Exp Psychol 29 (1941) 390-400
17. Fendt M., Burki H., Imobersteg S., Lingenhohl K., McAllister K.H., Orain D., Uzunov D.P., and Chaperon F. Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology (Berl) 206 2 (2009) 291-301
18. Fendt M., Koch M., and Schnitzler H.U. Corticotropin-releasing factor in the caudal pontine reticular nucleus mediates the expression of fear-potentiated startle in the rat. Eur J Neurosci 9 2 (1997) 299-305
19. Gale G.D., Anagnostaras S.G., Godsil B.P., Mitchell S., Nozawa T., Sage J.R., Wiltgen B., and Fanselow M.S. Role of the basolateral amygdala in the storage of fear memories across the adult lifetime of rats. J Neurosci 24 15 (2004) 3810-3815
20. Gehlert D.R., Cippitelli A., Thorsell A., Le A.D., Hipskind P.A., Hamdouchi C., Lu J., Hembre E.J., Cramer J., Song M., McKinzie D., Morin M., Ciccocioppo R., and Heilig M. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethy l-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 27 10 (2007) 2718-2726
21. Geller I., and Seifter J. The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia (Berl) 1 6 (1960) 482-492
22. Ghitza U.E., Nair S.G., Golden S.A., Gray S.M., Uejima J.L., Bossert J.M., and Shaham Y. Peptide YY3-36 decreases reinstatement of high-fat food seeking during dieting in a rat relapse model. J Neurosci 27 43 (2007) 11522-11532
23. Gleitman H., and Holmes P.A. Retention of incompletely learned CER in rats. Psychon Sci 7 1 (1967) 19-20
24. Golin S. Incubation effect: role of awareness in an immediate versus delayed test of conditioned emotionality. J Abnorm Soc Psychol 63 (1961) 534-539
25. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.P., and Soubrie P. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro- 4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301 1 (2002) 333-345
26. Gutman A.R., Yang Y., Ressler K.J., and Davis M. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J Neurosci 28 48 (2008) 12682-12690
27. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 38 4 (2004) 213-224
28. Heilig M., Koob G.F., Ekman R., and Britton K.T. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 17 2 (1994) 80-85
29. Heilig M., McLeod S., Brot M., Heinrichs S.C., Menzaghi F., Koob G.F., and Britton K.T. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 8 4 (1993) 357-363
30. Heilig M., McLeod S., Koob G.K., and Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41 1 (1992) 61-69
31. Hendersen R.W. Forgetting and conditioned fear inhibition. Learn Motiv 9 (1978) 16-30
32. Hikichi T., Akiyoshi J., Yamamoto Y., Tsutsumi T., Isogawa K., and Nagayama H. Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry 33 5 (2000) 189-193
33. Hokfelt T., Johansson O., and Goldstein M. Chemical anatomy of the brain. Science 225 4668 (1984) 1326-1334
34. Houston F.P., Stevenson G.D., McNaughton B.L., and Barnes C.A. Effects of age on the generalization and incubation of memory in the F344 rat. Learn Mem 6 2 (1999) 111-119
35. Hunt H.F., and Brady J.V. Some effects of electro-convulsive shock on a conditioned emotional response ("anxiety"). J Comp Physiol Psychol 44 1 (1951) 88-98
36. Kalin N.H., and Takahashi L.K. Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems. Brain Res 509 1 (1990) 80-84
37. Kask A., and Harro J. Inhibition of amphetamine- and apomorphine-induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304. Neuropharmacology 39 7 (2000) 1292-1302
38. Kask A., Harro J., von Horsten S., Redrobe J.P., Dumont Y., and Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 26 3 (2002) 259-283
39. Kask A., Rago L., and Harro J. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Eur J Pharmacol 317 2-3 (1996) R3-R4
40. Larhammar D., and Salaneck E. Molecular evolution of NPY receptor subtypes. Neuropeptides 38 4 (2004) 141-151
41. Le A.D., Harding S., Watchus W., Juzytsch W., Shalev U., and Shaham Y. The role of corticotropin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology 150 (2000) 317-324
42. Leibowitz S.F. Brain peptides and obesity: pharmacologic treatment. Obes Res 3 Suppl 4 (1995) 573S-589S
43. Levine A.S., and Morley J.E. Neuropeptide Y: a potent inducer of consummatory behavior in rats. Peptides 5 6 (1984) 1025-1029
44. Liu X., and Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22 18 (2002) 7856-7861
45. McAllister D.E., and McAllister W.R. Incubation of fear: an examination of the concept. J Exp Res Personal 2 (1967) 180-190
46. McMichael J.S. Incubation of anxiety and instrumental behavior. J Comp Physiol Psychol 61 2 (1966) 208-211
47. Menzaghi F., Howard R.L., Heinrichs S.C., Vale W., Rivier J., and Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 269 (1994) 564-572
48. Miczek K.A. Effects of scopolamine, amphetamine and benzodiazepines on conditioned suppression. Pharmacol Biochem Behav 1 4 (1973) 401-411
49. Millenson J.R., and Leslie J. The conditioned emotional response (CER) as a baseline for the study of anti-anxiety drugs. Neuropharmacology 13 1 (1974) 1-9
50. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 5th ed. (2005), Elsevier Academic Press, Amsterdam
51. Pickens C.L., Golden S.A., Adams-Deutsch T., Nair S.G., and Shaham Y. Long-lasting incubation of conditioned fear in rats. Biol Psychiatry 65 10 (2009) 881-886
52. Risbrough V.B., Geyer M.A., Hauger R.L., Coste S., Stenzel-Poore M., Wurst W., and Holsboer F. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology 34 6 (2009) 1494-1503
53. Sakai R.R., Ma L.Y., He P.F., and Fluharty S.J. Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat. Regul Pept 59 2 (1995) 183-192
54. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., Dunaiskis A., Faraci S., Schmidt A.W., Seeger T., Seymour P., Tingley III F.D., Winston E.N., Chen Y.L., and Heym J. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 93 19 (1996) 10477-10482
55. Scott V., Kimura N., Stark J.A., and Luckman S.M. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J Neuroendocrinol 17 7 (2005) 452-457
56. Skorzewska A., Bidzinski A., Hamed A., Lehner M., Turzynska D., Sobolewska A., Maciejak P., Szyndler J., Wislowska-Stanek A., and Plaznik A. The influence of CRF and alpha-helical CRF(9-41) on rat fear responses, c-Fos and CRF expression, and concentration of amino acids in brain structures. Horm Behav 54 5 (2008) 602-612
57. Swerdlow N.R., Britton K.T., and Koob G.F. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology 2 4 (1989) 285-292
58. Tovote P., Meyer M., Beck-Sickinger A.G., von Horsten S., Ove Ogren S., Spiess J., and Stiedl O. Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. Regul Pept 120 1-3 (2004) 205-214
59. Valdez G.R., Roberts A.J., Chan K., Davis H., Brennan M., Zorrilla E.P., and Koob G.F. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol Clin Exp Res 26 10 (2002) 1494-1501
60. Waddell J., Bouton M.E., and Falls W.A. Central CRF receptor antagonist a-helical CRF9-41 blocks reinstatement of extinguished fear: the role of the bed nucleus of the stria terminalis. Behav Neurosci 122 5 (2008) 1061-1069
61. Wahlestedt C., Yanaihara N., and Hakanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept 13 3-4 (1986) 307-318
62. Walker D., Yang Y., Ratti E., Corsi M., Trist D., and Davis M. Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses. Neuropsychopharmacology 34 6 (2009) 1533-1542
63. Walker D.L., and Davis M. Role of the extended amygdala in short-duration versus sustained fear: a tribute to Dr. Lennart Heimer. Brain Struct Funct 213 1-2 (2008) 29-42
64. Wieland H.A., Engel W., Eberlein W., Rudolf K., and Doods H.N. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 125 3 (1998) 549-555
65. Zorrilla E.P., and Koob G.F. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 13 7 (2004) 799-828